Literature DB >> 22150677

Alteronol inhibits proliferation in HeLa cells through inducing a G1-phase arrest.

Ying Yao1, Bo Zhang, Hongmei Chen, Na Chen, Liangliang Liu, Wang Yishan, Changling Li, Qiusheng Zheng.   

Abstract

OBJECTIVES: Alteronol is a novel compound purified from fermentation products of a microorganism in the bark of the yew tree. The study was designed to evaluate the anticancer effects of alteronol.
METHODS: Human cervical carcinoma cell line HeLa was cultured in vitro. The cell viability was evaluated by using sulforhodamine B assay. The cell cycle distribution was analysed by flow cytometry. The level of cyclin D1 protein was evaluated using Western blot analysis. The changes in cyclinD1, CDK4 and p21 were detected by ELISA assay and the changes in G1-related regulators were detected by RT-PCR assay. KEY
FINDINGS: Our data showed that alteronol inhibited the proliferation of HeLa cells and induced G1 phase arrest. Downregulation of the mRNA levels of CDK2, CDK4 and cyclin D1 and upregulation of p21 in alteronol-treated cells were observed.
CONCLUSIONS: Downregulation of the mRNA levels of CDK2, CDK4 and cyclin D1 and upregulation of p21 might be a possible mechanism for the inhibition of proliferation induced by alteronol in HeLa cells.
© 2011 The Authors. JPP © 2011 Royal Pharmaceutical Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22150677     DOI: 10.1111/j.2042-7158.2011.01375.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  1 in total

1.  Alternol eliminates excessive ATP production by disturbing Krebs cycle in prostate cancer.

Authors:  Changlin Li; Chenchen He; Ying Xu; Haixia Xu; Yuzhe Tang; Hemantkumar Chavan; Shaofeng Duan; Antonio Artigues; Marcus Laird Forrest; Partha Krishnamurthy; Suxia Han; Jeffrey M Holzbeierlein; Benyi Li
Journal:  Prostate       Date:  2019-01-20       Impact factor: 4.104

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.